糖皮质激素治疗支气管哮喘急性发作期患者血清IL-18、IL-33水平的变化及临床意义

目的 探讨糖皮质激素治疗支气管哮喘急性发作期血清IL-18和IL-33水平的变化.方法 采用ELISA对支气管哮喘急性发作期患者（观察组）糖皮质激素治疗前后IL-18、IL-33水平进行检测,并与正常人群（对照组）对比.结果 观察组IL-18、IL-33水平均明显高于对照组（P〈0.05）.糖皮质激素治疗后,观察组IL-18、IL-33水平降低（P〈0.05）;治疗6、12个月后,IL-18、IL-33水平低于治疗3个月后（P〈0.05）,治疗6、12个月后比较差异无统计学意义（P〉0.05）.结论 糖皮质激素是治疗支气管哮喘急性发作期的主要方法,其治疗作用可能与下调血清IL-18、IL-33水平有关,可以将检测血清IL-18、IL-33水平作为疗效评价的指标之一.

Clinical significance of IL-18 and IL-33 levels changes in the treatment of bronchial asthma with acute attack stage by glucocorticoids

Objective To explore the changes in the levels of serum IL-18 and IL-33 in the treatment of acute attack of bronchial asthma by glucocorticoids. Methods The ELISA was used to detect IL-18 and IL-33 before and after glucocorticoids treatment for acute attack of bronchial asthma patients（ observation group） ,and compared with normal population （control group ）. Results The IL-18 and IL-33 levels in observation group were significantly higher than those of control group（ P 〈 0. 05 ）. After glucocorticoid treatment,the IL-18 and IL-33 levels in observation group significantly decreased（P 〈 0. 05） ;the IL-18 and IL-33 levels at 6 months and 12 months after treatment were significantly lower than that at 3 months after treatment（ P 〈 0. 05 ）, but no significant difference was found between the levels at 6 months and 12 months after treatment（ P 〉 0.05 ）. Conclusion Glucocorticoid is the main treatment measure for acute attack of bronchial asthma, and the therapeutic effect may be related to down-regulation on serum IL-18 and IL-33 levels. Serum IL-18 and IL-33 level can be detected as one of the indicators to evaluate the clinical effect